Comparative analysis of histologic homologues of endometrial and ovarian carcinoma

American Journal of Surgical Pathology

Volumn 22, Issue 3, 1998, Pages 319-326

  Caduff, Rosmarie F ^a   Svoboda Newman, Suzette M ^a   Bartos, Rene E ^a   Ferguson, Amy W ^a   Frank, Thomas S ^a,b  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b Myriad Genetic Laboratories   (United States)

Author keywords

C erbB 2; Endometrial carcinoma; Ki ras; Loss of heterozygosity; Ovarian carcinoma; p53

Indexed keywords

ONCOPROTEIN; PROTEIN P53; TUMOR MARKER;

ARTICLE; CHROMOSOME 17Q; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE C ERB; OVARY CARCINOMA;

CARCINOMA; CHROMOSOMES, HUMAN, PAIR 17; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; OVARIAN NEOPLASMS; RAS PROTEINS; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031884184     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-199803000-00006     Document Type: Article

References (38)

1. The International Federation of Obstetrics and Gynecology stages - 1988 revision. Gynecol Oncol 1989;35:125-7.
2. Aberle H, Bierkamp C, Torchard D, et al. The human plakoglobin gene localizes on chromosome 17q21 and is subjected to loss of heterozygosity in breast and ovarian cancers. Proc Natl Acad Sci USA 1995;92:6384-8.
3. Banks L, Matlashewski G, Crawford L. Isolation of human p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 1986;159:529-34.
4. Barbacid M. ras genes. Ann Rev Biochem 1987;56:779-827.
5. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
6. Bur ME, Perlman C, Edelmann L, Fey E, Rose PG. p53 expression in neoplasms of the uterine corpus. Am J Clin Pathol 1992;98:81-7.
7. Caduff RF, Johnston CM, Frank TS. Mutations of the Ki-ras oncogene in carcinoma of the endometrium. Am J Pathol 1995;146:182-8.
8. Caduff RF, Johnston CM, Svoboda-Newman SM, Poy EL, Merajver SD, Frank TS. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 1996;148:1671-8.
9. Cunningham J, Lust JA, Schaid DJ, et al. Expression of p53 and 17p allelic loss in colorectal carcinoma. Cancer Res 1992;52:1974-80.
10. De Potter CR, Quatacker J, Maertens G, et al. The subcellular localization of the neu protein in human normal and neoplastic cells. Int J Cancer 1989;44:969-74.
11. Eccles DM, Russell SE, Haites NE, et al. Early loss of heterozygosity on 17q in ovarian cancer. The Abe Ovarian Cancer Genetics Group. Oncogene 1992;7:2069-72.
12. Enomoto T, Weghorst CM, Inoue M, Tanizawa O, Rice JM. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 1991;139:777-85.
13. Felip F, Del Campo JM, Rubio D, Vidal MT, Colomer R, Bermejo B. Overexpression of c-erbB-2 in epithelial ovarian cancer. Cancer 1995;75:2147-52.
14. Finlay CA, Hinds PW, Tan T-H, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-9.
15. Frank TS, Bartos RE, Haefner HK, Roberts JK, Wilson MD, Hubbell GP. Loss of heterozygosity and overexpression of the p53 gene in ovarian carcinoma. Mod Pathol 1994;7:3-8.
16. Frank TS, Svoboda-Newman SM, Hsi ED. Comparison of methods for extracting DNA from formalin fixed paraffin sections for non-isotopic PCR. Diagn Mol Pathol 1996;5:220-4.
17. Friedman LS, Lynch ED, King M-C. Two independent polymorphisms at the 17 beta-hydroxysteroid dehydrogenase (EDH17B) gene (17q21). Hum Mol Genet 1993;2:821.
18. Fujino T, Risinger JI, Collins NK, et al. Allelotype of endometrial carcinoma. Cancer Res 1994;54:4294-8.
19. Fujita M, Enomoto T, Wada H, Inoue M, Okudaira Y, Shroyer KR. Application of clonal analysis. Differential diagnosis for synchronous primary ovarian and endometrial cancers and metastatic cancer. Am J Clin Pathol 1996;105:350-9.
20. Godwin AK, Vanderveer L, Schultz DC, et al. A common region of deletion on chromosome 17 in both sporadic and familial epithelial ovarian tumors distal to BRCA1. Am J Hum Genet 1994;55:666-77.
21. Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podratz KC. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 1992;47:179-85.
22. Jacobs IJ, Smith SA, Wiseman RW, et al. A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus. Cancer Res 1993;53:1218-21.
23. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
24. Kerns BJ, Jordan PA, Moore MH, et al. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem 1992;40:1047-51.
25. Klemi P-J. Pylkkänen L, Kiilholma P, Kurvinen K, Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995;76:1201-8.
26. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992;89:7491-5.
27. Merajver SD, Frank TS, Xu J, et al. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer. Clin Cancer Res 1995;1:539-44.
28. Merajver SD, Pham TM, Caduff RF, et al. Somatic mutations in the BRCA1 in sporadic ovarian tumours. Nature Genetics 1995;9:439-43.
29. Nielsen AL, Nyholm HCJ. p53 protein and c-erbB-2 protein (p185) expression in endometrial adenocarcinoma of endometrioid type. An immunohistochemical examination on paraffin sections. Am J Clin Pathol 1994;102:76-9.
30. Pieretti M, Powell DE, Gallion HH, Case EA, Conway PS, Turker MS. Genetic alterations on chromosome 17 distinguish different types of epithelial ovarian tumors. Hum Pathol 1995;26:393-7.
31. Polymeropoulos MH, Rath DS, Xiao H, Merrill CR. A simple sequence repeat polymorphism at the human growth hormone locus. Nucleic Acids Research 1991;3:689.
32. Reinartz JJ, George E, Lindgren BR, Niehans GA. Expression of p53. transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 1994;25:1075-83.
33. Scully RE. Tumors of the ovary and maldeveloped gonads. In: Rosai J, ed. Atlas of Tumor Pathology. Washington, DC: Armed Forces Institute of Pathology: 1979:53-116.
34. Seizinger BR, Klinger HP, Junien C, et al. Report of the committee on chromosome and gene loss in human neoplasia. Cytogenet Cell Genet 1991;58:1080-96.
35. Shenson DL, Gallion HH, Powell DE, Pieretti M, Loss of hetero zygosity and genomic instability in synchronous endometrioid tumors of the ovary and endometriuin. Cancer 1995;76:650-7.
36. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors. Hum Pathol 1995;26:1268-74.
37. Silverberg SG, Kurman RJ. Tumors of the uterine corpus and gestational trophoblastic disease. In: Rosai J, ed. Atlas of Tumor Pathology. 3rd series. Washington, DC: Armed Forces Institute of Pathology; 1992:47-65.
38. Singleton TP, Niehans GA, Gu F, et al. Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. Hum Pathol 1992;23:1141-50.